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Background
Increased numbers of OX40+ T cells within the primary
tumor of colorectal cancer (CRC) patients has been asso-
ciated with improved survival. Similarly, OX40 expression
in sentinel lymph nodes is inversely associated with tumor
grade and clinical stage in melanoma patients. However,
the prevalence of OX40+ tumor-associated lymphocytes
remains underreported in many human solid tumor types.
In this study, we report prevalence of OX40 by chromo-
genic immunohistochemistry in melanoma, colorectal,
bladder, renal cell (RCC), triple-negative breast (TNBC),
non-small cell lung (NCSCLC) and ovarian cancers and its
association with available clinical parameters.
Methods
Tumor-associated OX40+ cells in melanoma (n=40), blad-
der (n=51), CRC (n=40), NSCLC (n=40), TNBC (n=45),
ovarian (n=40) and RCC (n=42) patient samples including
primary site and a subset of matched metastases have
been stained for OX40 using a DAB-based chromogenic
immunohistochemistry assay. Stained sections have been
independently scored for OX40+ lymphocyte area percen-
tage by two pathologists and a subset will be digitally
imaged and analyzed. Image analysis includes OX40+ lym-
phocyte enumeration and area calculation within patholo-
gist-defined regions of interest (ROI) to include the tumor
and surrounding stroma. OX40 prevalence (OX40-positive
cells/mm2 and % OX40+ cell area) were compared with
patient age, clinical parameters, and outcome, where avail-
able, to determine potential associations.
Results
Results to be reported include a.) pathologist scoring of
OX40+ cell prevalence b.) image analysis of OX40+ cell
number and area percentage in a subset of indications
c.) concordance between image analysis and patholo-
gists’ scores d.) OX40 prevalence by tumor type e.)
OX40 prevalence and association with clinical features,
where available, and statistical significance.
Conclusions
Prevalence of OX40 expression and association with
clinical features are first reported in some solid tumor
types.
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